T. Rowe Price Associates’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $5.9M | Sell |
|
|||||
|
2025
Q2 | $123M | Sell |
|
|||||
|
2025
Q1 | $116M | Sell |
|
|||||
|
2024
Q4 | $181M | Buy |
|
|||||
|
2024
Q3 | $150M | Buy |
|
|||||
|
2024
Q2 | $113M | Buy |
|
|||||
|
2024
Q1 | $107M | Sell |
|
|||||
|
2023
Q4 | $140M | Buy |
|
|||||
|
2023
Q3 | $121M | Buy |
|
|||||
|
2023
Q2 | $99.1M | Buy |
|
|||||
|
2023
Q1 | $17.8M | Buy |
|
|||||
|
2022
Q4 | $8.64M | Sell |
|
|||||
|
2022
Q3 | $6.92M | Sell |
|
|||||
|
2022
Q2 | $4.44M | Buy |
|
|||||
|
2022
Q1 | $6.29M | Sell |
|
|||||
|
2021
Q4 | $7.39M | Sell |
|
|||||
|
2021
Q3 | $7.46M | Hold |
|
|||||
|
2021
Q2 | $7.81M | Sell |
|
|||||
|
2021
Q1 | $8.11M | Buy |
|
|||||
|
2020
Q4 | $8.53M | Buy |
|